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Anti-TNF treatment is effective in a majority of rheumatoid arthritis (RA), however, this treatment
can unexpectedly trigger the onset or exacerbate multiple sclerosis (MS). Recent progress in cellular
immunology research provides a new framework to analyze the possible mechanism underlying
these puzzling contradictory effects. The delicate balance of protective CD4+FoxP3+ regulatory T cells
(Tregs) and pathogenic CD4+FoxP3 effector T cells (Teffs) is crucial for the outcome of anti-TNF
treatment of autoimmune disease. There is convincing evidence that TNF, in addition to stimulating
Teffs, is able to activate and expand Tregs through TNFR2, which is preferentially expressed by Tregs.
Therefore, the contrasting effects of TNF on Tregs and Teffs are likely to determine the therapeutic
effect of anti-TNF treatment. In this review, we discuss the current understanding of the general
effect of TNF on the activation of T cells, and the impact of TNF on the function of Teffs and Tregs.
Understanding the differential effects of TNF on Teffs and Tregs is fundamentally required for the
design of more effective and safer anti-TNF or anti-TNF receptor(s) therapeutic strategy for autoim-
mune diseases.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
1.1. Contrasting immunopathogenic and immunoprotective effects of
TNF
The pleiotropic cytokine tumor necrosis factor-alpha (TNF) is a
major participant in the initiation and orchestration of complex
events in inﬂammation and immunity [1]. Upon stimulation by
pathogens and inﬂammatory signaling, TNF is produced primarily
by immune cells, such as macrophages and T and B lymphocytes,
as well as by other somatic cell types, including endothelial cells,
mast cells, neuronal tissues and tumor cells [2,3]. Initially, trans-
membrane TNF is synthesized [4], and it can be subsequently re-
leased as soluble TNF (sTNF) upon cleavage by the
metalloprotease TNF-a-converting enzyme (TACE or ADAM17)
[5]. Both the soluble and transmembrane forms of TNF are biologi-
cally active in their trimeric forms [5].lf of the Federation of European Bi
tal autoimmune encephalo-
sclerosis; mTNF, membrane-
eral blood; RA, rheumatoid
egs, regulatory T cells; Trx-1,
heim).The effects of TNF are mediated by two structurally related, but
functionally distinct receptors, TNFR1 (or p55) and TNFR2 (or p75)
[6]. These receptors also can be released from the cell surface as
soluble forms by proteolysis and have the capacity to neutralize
the action of TNF [7,8]. In contrast to the ubiquitous expression
of TNFR1, TNFR2 is more restricted to lymphocytes and is more
efﬁciently activated by transmembrane as opposed to sTNF [9].
TNFR1 with its death domain (DD) is the primary signaling recep-
tor on most cell types and accounts for the majority of the proin-
ﬂammatory, cytotoxic and apoptotic effects classically attributed
to TNF [10,11]. In contrast, TNFR2 lacks an intracellular death do-
main and predominantly mediates signals promoting lymphocyte
activation and proliferation [12,13].
TNF has well-documented proinﬂammatory effects. Neverthe-
less, increasing evidence reveals that TNF also has unexpected
anti-inﬂammatory and immunosuppressive effect, especially after
prolonged exposure (reviewed in Refs. [14–16]). Several transgenic
mouse strains overproducing TNF consistently develop autoim-
mune disorders (reviewed in Ref. [17]). However, transgenic non-
obese diabetic (NOD) mice over-expressing TNF in their pancreatic
islets failed to develop autoimmune diabetes [18] and repeated
injection of TNF paradoxically suppressed both type I diabetes in
NOD mice and lupus nephritis in susceptible mouse strains [19].
Furthermore, NZB mice deﬁcient in TNF unexpectedly exhibited
acceleration of autoimmunity and lupus nephritis [20]. C57BL/ochemical Societies.
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bling the initial stages of lupus nephritis [21]. TNF knockout (KO)
mice developed prolonged and exacerbated experimental autoim-
mune encephalomyelitis (EAE), although with a delayed onset,
after EAE induction [22]. Thus, in mouse models of autoimmunity,
TNF can either promote or inhibit inﬂammatory responses
depending on complex factors which may include disease stage,
background genetic susceptibility, length and timing of TNF
expression.
Anti-TNF therapy is clearly beneﬁcial for most of rheumatoid
arthritis (RA) patients. Perhaps reﬂecting the strikingly contrasting
activities of TNF, anti-TNF therapy in patients with RA and inﬂam-
matory bowel disease (IBD), however, a minority of patients devel-
op lupus and neuroinﬂammatory diseases [21]. Furthermore,
multiple sclerosis (MS) patients treated with anti-TNF agents re-
sulted almost uniformly in immune activation and exacerbation
of disease [21]. To date, the cellular and molecular mechanism
underlying the contrasting proinﬂammatory and immunosuppres-
sive effect of TNF, as well as anti-TNF agents, in autoimmunity re-
main to be clariﬁed.
1.2. Immune equilibrium between regulatory T cells and effector T cells
determines the outcome of autoimmune responses
Extensive studies provide compelling evidence that CD4+FoxP3+
regulatory T cells (Tregs) play an indispensable role in maintaining
immune homeostasis and in suppressing deleterious excessive im-
mune responses [23]. The induction of Treg suppressive activity is
antigen speciﬁc and requires stimulation through the TCR, how-
ever, the suppressive function of Tregs is not antigen speciﬁc
[24]. Therefore, a wide range of immune responses can be inhibited
by Tregs through ‘‘bystander’’ suppression [25]. It is known that
the cellular targets of Tregs include CD4 cells [26], CD8 cells [27],
NK cells [28], NKT cells [29], dendritic cells (DCs) [30],
macrophages [31] and B cells [32]. The in vitro suppressive activity
of Tregs depends on cell-to-cell contact [26]. Several molecules,
such as IL-10, TGFb, CTLA-4, IDO and granzyme/perforin are re-
ported to contribute to the suppressive activity of Tregs (reviewed
in Ref. [33]). However, the exact molecular mechanisms responsi-
ble for the cell contact dependent suppression by Tregs remain
elusive.
Autoreactive effector T cells (Teffs) exist even in the healthy
individual and their activation is persistently suppressed by Tregs,
since removal of Tregs can result in the expansion and activation of
these autoreactive Teffs [34]. Breakdown of tolerance by favoring
the activities of Teffs over Tregs is a hallmark of autoimmune dis-
eases [23]. The outcome of the autoimmune process is therefore
largely determined by factors which tip the balance between the
activation of Teffs and Tregs. The immune equilibrium between
Teffs and Tregs, therefore, determines the cellular and molecular
basis of immunopathological and immunoprotective effects of
TNF. The capacity of TNF to expand the pool of functional Tregs
represents the major negative feedback loop by which TNF coun-
ters its potent pro-inﬂammatory effects.
1.3. The complex relationship between protective Tregs and pathogenic
Th17 cells
Upon activation by antigenic and cytokine stimulation, naïve
CD4 cells can differentiate into different lineages of T helper sub-
sets with an unique cytokine proﬁle and effector functions [35].
Recent compelling evidence shows that IL-17-producing T lympho-
cytes comprise a distinct lineage of proinﬂammatory T helper cells,
termed Th17 cells, that are major contributors to autoimmune dis-
ease [36,37]. Intriguingly, both Th17 cells and immunosuppressive
Tregs derived from naïve CD4 cells can be reciprocally induced,contingent upon the presence of either IL-6 or IL-2, respectively,
in the presence of TGFb [37–39]. However, during the process of
differentiation, both FoxP3 and RORct, the transcription factors
speciﬁc for Tregs and Th17 cells respectively, can occasionally be
expressed by one cell at the same time [40]. Furthermore, it has
been shown that Tregs exhibit ‘‘plasticity’’ and can become IL-17-
producing cells after treatment with IL-6 both in vitro [41] and
in vivo [42,43]. The functional relationship of Th17 and Tregs is
also complicated. It has been clearly shown that both Th1 and
Th2 responses can be potently suppressed by Tregs, however,
Th17 responses are not always susceptible to Treg-mediated inhi-
bition [44–46]. Actually, Tregs can promote in vitro generation of
Th17 cells [39], as conﬁrmed by our own experiments. This para-
doxical effect of Tregs has pathophysiological relevance, since in
a model of a T cell-mediated systemic autoimmune disorder
resembling graft-versus-host disease, adoptive transfer of Tregs
promoted the generation of Th17 cells [47]. Thus, the complex con-
version to and support by Tregs of Th17 cells may also contribute
to the puzzling effect of TNF and anti-TNF on the outcome of an
autoimmune inﬂammation.
T cells play a critical role in the initiation and sustain an inﬂam-
matory response, nevertheless, many other types of cells are also
involved in the pathogenesis of autoimmune disorders [48]. The di-
rect and indirect responses of these non-T cells to anti-TNF,
although representing major aspect of therapeutic effect, are be-
yond the scope of this review.2. TNF activates Tregs through TNFR2
2.1. Human and mouse Tregs preferentially express high levels of
TNFR2
We found that the majority (>80%) of thymic Tregs in normal
mice express TNFR2 [49]. In normal mouse peripheral lymphoid
tissues, TNFR2 is expressed primarily by CD4 T cells, in contrast,
CD8 T cells express markedly lower levels of TNFR2 [49]. Compared
with thymic Tregs, TNFR2-expressing Tregs are reduced to 30–40%
in the peripheral lymphoid organs and further reduced to 10% in
the circulation. Nevertheless, TNFR2 is still preferentially ex-
pressed by Tregs, since fewer than 10% of Teffs in the LNs and
spleen of normal mice express lower levels of TNFR2 on a per cell
basis [49,50].
TNF is expressed in human and mouse thymus and participates
the development of thymocytes [51–53]. It is possible that either
TNF or LTa, which also uses TNFR2, actually contribute to the thy-
mic differentiation and generation of Tregs. Similar to their mouse
counterparts, all human thymic Tregs, but not conventional thy-
mocytes, express TNFR2 [54]. Recently it has been shown that
TNF-TNFR2 interaction plays a critical role in the expansion of hu-
man CD4+ and CD8+ Tregs [55,56]. Although TNF does not convert,
but proliferatively expands FoxP3+ Tregs in the periphery. Human
circulating FoxP3+ cells present in CD25hi, CD25low and even CD25
subsets of CD4+ cells expressed markedly higher levels of TNFR2
(70%), as compared with CD4+FoxP3 Teffs (20%) [50,57,58].
TNFR2 is also expressed on antigen-speciﬁc CD4 Tregs induced
by tolerogeneic DCs [55] and CD8+ Tregs generated by anti-CD3
treatment [56]. The functional implications of TNFR2 in human
Treg activity also are becoming evident. For example, both acti-
vated human and mouse Tregs produce high levels of sTNFR2
which contribute to their immunosuppressive activity [57]. TNF–
TNFR2 interaction promotes the survival of Tregs in cancer and
at inﬂammatory sites by inducing thioredoxin-1, a major antioxi-
dative molecule, of Tregs in a NFjB-dependent manner [59]. Fur-
thermore, as in mice, TNF-TNFR2 interaction increases FoxP3
expression by human Tregs (our unpublished data).
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Importantly, the expression of TNFR2 actually identiﬁes the
maximally suppressive subset of mouse Tregs [49,50]. For example,
the majority of tumor inﬁltrating Tregs are highly suppressive
TNFR2+ cells [49], and depletion of TNFR2+ Tregs results in tumor
eradication after cyclophosphamide treatment [60]. TNFR2+ Tregs
are highly proliferative in vivo presumably upon inﬂammatory
stimulation by self antigens and TNF/LTa [50]. Tregs deﬁcient in
TNFR2 are not able to control inﬂammatory responses in vivo
[57]. In an ongoing inﬂammatory condition, up-regulation of
TNFR2 expression on human Tregs also can serve as an indicator
of more suppressive Tregs, as shown in malaria patients [61].
TNFR2 expression on human Tregs present in the synovial ﬂuid
of RA patients is also up-regulated [58], presumably reﬂecting their
enhanced suppressive capacity [62]. It is not clear why
TNFR2+FoxP3+ Tregs are more functionally suppressive.
2.3. TNF-TNFR2 interaction co-stimulates activation of T cells
It is well known that TNF has the capacity to promote TCR-
dependent T cell activation [63], an effect attributed to the optimal
activation of NFjB by TNF [64]. Interaction of TNF with TNFR2, but
not TNFR1, is directly co-stimulatory to TCR-mediated T cell activa-
tion, as demonstrated by the effects of agonistic monoclonal anti-
bodies to TNFR2 on human CD4 cells [65]. TNFR2 KO mouse
studies further conﬁrmed the role of TNFR2 as a T cell co-stimula-
tory molecule. TNFR2 deﬁciency resulted in the reduced prolifera-
tive ability of CD4 cells as well as CD8 cells, and decreased
production of IFNc, TNF and IL-2 expression in response to TCR
stimulation [66–68]. Remarkably, co-stimulations via TNFR2 and
CD28 have different cellular effects and signaling requirements
[65], and activation of CD28 is unable to rescue the defective re-
sponse of TNFR2-deﬁcient T cells to TCR stimulation [23], indica-
tive of an unique and non-redundant co-stimulatory role of
TNFR2 on T cells. Furthermore, these studies also revealed that
TNFR2 is important for the survival of T cells during a proliferative
response and this was associated with up-regulation of anti-apop-
totic molecules such as Bcl-xL, Bcl-2 and survivin [66,67]. T cell-de-
rived TNF appears to be crucial for the co-stimulation of T cells
[69]. Intriguingly, a recent study reports that TNF produced by
the activated Teffs is necessary for the stimulation of expansion
and enhancement of suppressive function of Tregs [70]. This study
in agreement with our previous observation that TNF, in addition
to activating Teffs, has the capacity to activate and expand Tregs
[71].
2.4. Prolonged interaction of TNF-TNFR2 impairs TCR signaling
Although relatively brief exposure to TNF has a co-stimulatory
effect on T cells, its role after prolonged exposure appears to be
quite different. Chronic exposure to rTNF led to impaired produc-
tion of cytokines such as IL-2, IFNc, IL-4, IL-10, TNF and LT from
both human T cells and T cells from TCR-tg mice [72,73] (reviewed
in Ref. [15]). Attenuation of T cell activation was associated with
defective Ca2+ responses and could be partly attributed to de-
creased surface CD3f expression and attenuated LAT and PLCc
tyrosine phosphorylation [74] or down-regulation of CD28 expres-
sion [75], indicating that intact proximal TCR signaling can be dis-
rupted by chronic TNFR signaling. This inhibitory effect of chronic
TNF on human T cell activation was shown to be TNFR2-dependent
[76]. In human CD4 and CD8 T cells, prolonged cross-linking TNFR2
had the capacity to down-regulate TCR/CD28-induced Ca2+ mobili-
zation, inhibited the expression of IL-2 mRNA and production of IL-
2 and IL-10, indicating that persistent TNFR2 ligation can have neg-
ative effects on TCR-dependent signaling [65]. It is unclear whetherchronic TNF stimulation or TNFR2 ligation attenuates TCR signaling
in both Treg and Teff cells in the same manner. Since TNFR2 is pre-
dominantly expressed by humans and mouse Tregs [49,50,57,58],
TCR signalling of Tregs is likely to be more profoundly affected
by chronic TNF stimulation. It is possible that the previously ob-
served down-regulation of TCR signalling in unfractionated T cells
could result from the increased suppressive capacity of Tregs
which can be activated and expanded by chronic TNF exposure.
This scenario is supported by the accumulation of highly suppres-
sive Tregs in the inﬂamed synovial ﬂuid of RA patients [77]. Further
study is warranted to elucidate these possibilities.
2.5. The role of TNFR1 in the activation of T cells
Although TNFR2 has been widely accepted as a co-stimulatory
molecule of T cells, the ubiquitously expressed TNFR1 also contrib-
utes to T cell activation.Unlike other deathdomain receptors, TNFR1
is a TNF receptor-associated factor 2-binding receptor [78] that ini-
tiates cell activation, stimulatedifferentiation andpromote survival.
Based on studies of TNFR1 KOmice, TNFR1was found to plays a crit-
ical role in T cell responses to alloantigen [79] and autoantigen [80].
Recently, it was reported that TNFR1 can also act as a positive co-
stimulatory molecule that is necessary for the initiation of T cell re-
sponses [81] and promotes T cell survival [82]. TNFR1 may mediate
the suppressive effect of TNFonT cell activation. For example, TNFR1
was reported to mediated the effect of TNF on the impairment of
proximal TCR signaling in mouse and Jurkat T cells [83]. We have
shown that Treg-activating effect of TNF is mediated by TNFR2
[71], further study is needed to examinewhether TNF–TNFR1 inter-
action would preferentially activate Teffs.3. The responses of Teffs and Tregs to TNF and anti-TNF agents
3.1. TNF–TNFR2 interaction increases the resistance of Teffs to Treg-
mediated inhibition
Our current understanding regarding the effects of TNF on the
function of Teffs was mainly shaped by studies based on TNF KO
and TNFR KO mice. For example, TNF KO mice are highly suscepti-
ble to challenge with an infectious agent (Candida albicans), and are
resistant to the lethal dose of lipopolysaccharide (LPS) [84], sug-
gesting critical role of TNF in T cell immunity. This view point
has been veriﬁed by the observation that the risk of serious infec-
tions and malignancies was increased in patients with RA treated
with anti-TNF antibody therapy [85]. The role of TNF in T cell im-
mune responses has been extensively reviewed [86].
A recent study from our lab has provided new insight concern-
ing the role of TNF-TNFR2 signaling in the activation of Teffs in the
presence of persistent exposure of Tregs. We conﬁrmed reports of
other groups that exogenous TNF could promote proliferative re-
sponses and cytokine production of Teffs to TCR stimulation [71].
Furthermore, Teffs proliferated despite the presence of Tregs dur-
ing a brief period of stimulation with TNF, although more pro-
longed treatment with TNF restored the suppression by Tregs
[71]. This effect of TNF on Teffs became more dramatic when it
was combined with IL-1b and IL-6 [87]. TNFR2 is expressed at very
low levels of <10% on resting Teffs, but can be quickly induced by
TCR stimulation to 30% even in the presence of Tregs [71]. TNFR2
is associated with greater suppressive functions when expressed
by Treg cells, but is also associated with greater resistance to sup-
pression when expressed by Teff cells. In mice bearing 4T1 breast
tumor or Lewis lung carcinoma (LLC), intratumoral Teff cells
expressing elevated levels of TNFR2 acquired the capacity to resist
suppression by lymph node (LN)-derived Treg cells. However, they
remained susceptible to inhibition by more suppressive tumor
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data indicate that TNFR2 also co-stimulates Teff cells and induces
their resistance to Tregs [50]. This is supported by a previous study
showing that TNF–TNFR2 signals were critical for effective prim-
ing, proliferation, and recruitment of tumor-speciﬁc immunoreac-
tive Teff cells [88].
3.2. Effect of TNF on differentiation of pathogenic Th17 cells
The effect of TNF on the Th17 responses could provide a key to
demystify the puzzling action of TNF and anti-TNF treatment in
autoimmunity. An initial report indicated that TNF had the capacity
to amplify the generation of Th17 cells by IL-6 and TGFb1 [39]. How-
ever, this has not been conﬁrmed by our own data and many other
reports. Furthermore, neutralization of TNF with murine TNFR2-Fc
fusion protein surprisingly exacerbated skin inﬂammation and
markedly enhanced Th17 function and expression of the proinﬂam-
matory cytokines such as IL-1b, IL-6, IL-17, IL-21, and IL-22, but sup-
pressed FoxP3 expression in the skin and reduced the number of
FoxP3-positive Treg cells in the draining LNs [89]. Thus, the surpris-
ing effect of TNF blockade on stimulating Th17 response and inhib-
iting Treg activity may account for the exacerbation of skin
inﬂammation in some patients who receive anti-TNF treatments.
This has been conﬁrmed in a mouse model of RA, in which TNF
blockade using TNFR-Fc fusion protein or anti-TNF monoclonal
antibody reduced the severity of arthritis but, unexpectedly, ex-
panded the populations of Th1 and Th17 cells, which were shown
by adoptive transfer to be pathogenic. Th1 and Th17 cell popula-
tions were also expanded in collagen-immunized TNFR p55(/)
but not p75(/) mice. The expression of IL-12/IL-23 p40 was
up-regulated in LN from p55(/) mice, and the expansion of
Th1/Th17 cells was abrogated by blockade of p40. Treatment of
macrophages with rTNF also inhibited p40 production in vitro.
These ﬁndings indicate that at least one of the ways in which
TNF–TNFR2 interactions regulate Th1/Th17 responses in arthritis
is by down-regulating the expression of p40. Although TNF block-
ade increased the numbers of Th1 and Th17 cells in LN, it inhibited
their accumulation in the joint, thereby providing an explanation
for the paradox that anti-TNF therapy ameliorates arthritis despite
increasing numbers of pathogenic T cells [90]. The results of this
mouse model study have been conﬁrmed by a human study. In
RA patients, Th17 cells and IL-17 production increase after anti-
TNF therapy, irrespective of disease activity. CCR6 expression is
up-regulated on Th17 cells, but RA patients in remission on anti-
TNF therapy have signiﬁcantly lower expression than those with
active disease. The increase in peripheral Th17 cells in RA patients
after anti-TNF therapy is accompanied by a decrease in Th17-spe-
ciﬁc CCR6 expression, which might prevent homing of these poten-
tially pro-inﬂammatory cells to the synovium [91].
Taken together, this data suggest that TNF may suppress Th17
responses, while promoting Treg activity. Blockade of TNF thus
has the potential to promote Th17 responses at the expense of Treg
activity, which together exaggerate autoimmune inﬂammation. In
contrast, with the effects of anti-TNF in RA, suppression of TNF has
no effects on SLE and even exacerbates MS. It would be simplest to
propose this to be due to greater interference with Tregs rather
than with Teffs, but this remains to be clearly established since
other factors such as impaired penetration of the blood-brain bar-
rier and a role for non-TNF dependent inﬂammatory mediators
may be contributing.
3.3. Interaction of TNF and TNFR2 is crucial for the generation and
suppressive function of human Tregs
We and others have shown that, as in mice, human Tregs also
express characteristically high levels of TNFR2 [50,54,57,58]. Thus,we favor the idea of Bilate [92] that, as an evolutionarily conserved
innate and adaptive cytokine, TNF should similarly activate human
Tregs as well. Indeed, our own preliminary data suggest that TNF
could activate normal human Tregs (data not shown). More recent
studies discussed in the following sections also lend support to this
notion.
For example, vitamin D3-treated DCs (VD3-DCs) are able to in-
duce human CD4+FoxP3+ Tregs that suppress proliferation of re-
sponder T cells in vitro [93]. One characteristic of such
tolerogenic VD3-DCs is their unique capacity to produce large
amounts of TNF [94], and to express markedly higher levels of
membrane-bound TNF (mTNF) than untreated DCs [55]. Impor-
tantly, inhibition of TNF with anti-human TNF Ab (adalimumab,
blocking both sTNF and mTNF) during induction of Tregs by
VD3-DCs abrogates the suppressive function of Tregs. Furthermore,
blocking TNFR2 by anti-human CD120b Ab (hTNFR-M1) during
Treg induction similarly abrogated their subsequent suppressive
function. In contrast, etanercept, a TNFR2-Fc fusion protein which
mainly blocks sTNF, did not change the suppressive capacity of
Tregs. This study thus indicates that interaction of mTNF expressed
on tolerogenic DCs with TNFR2 expressed on Tregs is crucial for the
induction of suppressive function of human CD4 Tregs [55]. In an-
other example, anti-CD3 mAb OKT3 can also induce FoxP3 expres-
sion and suppressive function of human CD4 cells [95], it would be
interesting to ask whether TNF plays a role or not, since it was re-
ported that the induction of CD8+ Tregs by anti-CD3 mAb was also
TNF-dependent [56].
3.4. TNF promotes the survival and function of Tregs in the
inﬂammatory environment
Accumulation of Tregs in different cancers and inﬂammatory
diseases may result from aberrant proliferation as well as greater
resistance to oxidative stress compared with conventional T cells.
It was shown that freshly isolated Tregs are resistant to oxidative
stress-induced cell death compared with Teff cells and maintain
their suppressive function, even at H2O2 dosages lethal for Teffs
[96]. Human Tregs express and secrete higher levels of thiore-
doxin-1 (Trx-1), a major antioxidative molecule. Trx-1 has an
essential role in maintaining their surface thiol density as the ﬁrst
line of antioxidative defense mechanisms [59]. Inﬂammatory stim-
uli led to an up-regulation of Trx-1 expression on Tregs, but only
TNF increased Trx-1 release. In conjunction with increased expres-
sion and secretion of Trx-1 on Tregs but not on Teffs, TNF also en-
hanced surface thiol expression and consequently increased their
resistance to H2O2. This effect of TNF on Tregs was NFjB-depen-
dent, since inhibition of NFjB abolished the TNF-induced increase
of surface thiols as well as Trx-1 secretion [59]. Similar to our
observation of collaborative effects of IL-2 and TNF on the up-reg-
ulation of FoxP3 expression and suppressive function of mouse
Tregs, IL-2 also synergized with TNF in the induction of Trx-1 re-
lease [59]. In agreement with the conclusion drawn from our
mouse Treg study, this study clearly indicates that TNF represents
a dynamic anti-inﬂammatory feedback mechanism that promotes
Treg activity within inﬂammatory milieus to prevent prolonged
or excessive immune responses.
3.5. In vitro effect of TNF on the function of human Tregs
Since TNF clearly stimulates TNFR2+ Tregs, what accounts for
the therapeutically beneﬁcial effects of anti-TNF in RA? Ehrenstein
and colleagues studied the effect of exogenous TNF (0.1–5 ng/ml)
on co-cultures of CD4+CD25hi cells and CD4+CD25 cells from nor-
mal human healthy donors or from RA patients responsive to anti-
TNF therapy. Their results showed that exogenous TNF neither in-
creased nor decreased PB Treg activity, as evidenced by no alter-
X. Chen, J.J. Oppenheim / FEBS Letters 585 (2011) 3611–3618 3615ation of percentage inhibition of proliferation in the co-cultures
[97]. Another study also did not detect any impact of exogenous
TNF on Tregs [98]. Valencia and colleagues examined the effect
of higher concentrations of TNF (50 ng/ml) on in vitro normal hu-
man Treg activity. They reported that exogenous TNF down-regu-
lated FoxP3 expression and blocked Treg suppressive activity by
signaling through TNFR2 and that an agonist monoclonal antibody
to TNFR2 also reversed the suppressive activity of healthy donor PB
CD4+CD25hi cells [99]. In agreement with the results of this study,
Nagar and colleagues recently reported that although FoxP3 ex-
pressed by Tregs was not down-regulated by TNF, TNF decreased
the suppressive activity of human peripheral blood (PB) CD45RA
Tregs, based on their evidence that TNF stimulated the prolifera-
tion and cytokine production in co-cultures of Tregs and Teffs
[58]. However, rather than decreasing Treg activity, their results
may be attributable to the capacity of TNF to enhance the response
of Teffs to TCR stimulation. Nagar et al.’s report showing that the
levels of TNF-induced INFc in their Treg-Teff co-cultures actually
paralleled the levels in unstimulated co-cultures [58], indicating
that the degree of suppression by Tregs was not really diminished
by TNF. Consequently, the beneﬁcial effect of anti-TNF therapy
may partly result from restoring the equilibrium between Teffs
and Tregs by suppressing the activation of Teffs and sensitizing
Teffs to Treg-mediated inhibition.
3.6. Effects of anti-TNF treatment on the function of Tregs
TNF is generally considered to have major proinﬂammatory ef-
fects in autoimmune diseases based on studies of the anti-inﬂam-
matory effects of anti-TNF. Several such studies also show that
both expression levels of FoxP3 and suppressive function of
CD4+CD25hi cells are increased after neutralization of TNF [97,99].
Since anti-TNF treatment effectively suppresses autoimmune re-
sponses and Tregs are potent suppressors of autoreactive cells, it
is therefore logical to predict that anti-TNF should restore or im-
prove Treg activity [97,99]. However, these clinical results need to
be interpreted more carefully, simply because the proportion of
activated CD25hi Teffs contaminating the ‘‘CD4+CD25hi Treg’’ popu-
lation could also be reduced by anti-TNF treatment. The studies
claim that anti-TNF treatment reduce apoptosis of Tregs in RA
[100] may neglect the possibility that the replication of Tregs in
an inﬂamed site may also be reduced by neutralization of TNF
[48,101]. Furthermore, ‘‘Tregs’’ reportedly reduced by anti-TNF
treatment in autoimmune patients or animal models, are actually
not bona ﬁde naturally occurring CD4+FoxP3+ Tregs [97,102,103],
but are likely to be IL-10-producing Tr1 or TGFb-expressing Th3
cells (see our review in [77] for detailed discussion).
Recently, accumulating evidence points in the opposite direc-
tion, that anti-TNF at times eliminates Treg activity. For example,
in the mouse psoriasis model, anti-TNF therapy suppressed FoxP3
expression in the skin and the number of FoxP3-positive Treg cells
was reduced in the draining LNs [89]. The stimulatory effect of
pathogenic Teffs on Tregs could also be attenuated by neutraliza-
tion of TNF [104]. Induction of suppressive function of Ag-speciﬁc
human CD4+ Tregs by VD3-treated tolerogenic DCs [55] or human
CD8+ Tregs by anti-CD3 mAb were blocked by anti-TNF or anti-
TNFR2 Abs [56]. Further studies are warranted to determine
whether impaired Treg activity is responsible for the non-respon-
siveness or detrimental effect of anti-TNF agents in some autoim-
mune disorders.
One approach to avoid potential impairment of Treg activity by
neutralizing TNF is to selectively block interaction of TNF with
TNFR1, the primary signaling receptor that initiates the majority
of inﬂammatory responses classically attributed to TNF. A recent
study showed that treatment with a TNFR1 inhibitor dramatically
inhibited the development of mouse EAE and suppressed Th1 andTh17 responses as well as inﬁltration of inﬂammatory cells into the
CNS [105]. Presumably, blockade of TNF–TNFR1 interaction will
still allow the activation of Tregs through the TNF-TNFR2 pathway,
and the activated Tregs are able to consequently contribute to the
inhibition of autoimmune responses.4. Concluding remarks
TNF can co-stimulate both Tregs and Teffs and this effect is
likely to be mediated by the same receptor, TNFR2. In the resting
state, TNFR2 is constitutively expressed by mouse and human
Tregs, while markedly lower proportion of Teffs express low levels
of TNFR2. Upon TCR stimulation, expression of TNFR2 is also up-
regulated on Teffs, but still at markedly lower levels than TNFR2
expression on activated Tregs [49,71,106], suggesting that TNF–
TNFR2 co-stimulatory pathway may preferentially activate Tregs.
We favor a biphasic model: at the initial stage of host immune re-
sponses, TNF co-stimulates the activation of Teffs and liberates
them from the suppressive effects of Tregs, and enables them to
mount an effective immune responses against pathogens; at the la-
ter stage, higher levels of TNFR2 expression by Tregs enables them
to outcompete Teffs for TNF. TNF–TNFR2 co-stimulated activation
of Tregs may therefore account for the accumulation of activated
Tregs found in more prolonged inﬂammatory responses as in auto-
immunity, sepsis, some infection and tumors, and may also ac-
count for immunosuppression seen in the chronic exposure to
TNF. The stimulatory effect of TNF on Tregs thus represents an
important anti-inﬂammatory feedback mechanism responsible
for the attenuation and termination of prolonged or excessive im-
mune responses, which otherwise may cause severe collateral
damage (Fig 1).
The biphasic effect of TNF on Teffs and Tregs may underlie both
beneﬁcial and detrimental effects of anti-TNF treatment in autoim-
munity, by following three means. First, since TNFR2 is constitu-
tively expressed on the most suppressive Tregs, while its
expression on Teffs need to be induced and can be down-regulated
by neutralization of TNF (our unpublished observation), it is possi-
ble that the beneﬁcial effect of anti-TNF treatment is achieved in
part by suppressing TNFR2 expression on Teffs and consequently
sensitizing Teffs to Treg-mediated inhibition. Second, since provid-
ing TNF is critically required for the activation and proliferative
expansion of Tregs, blockade of TNF may result in the down-regu-
lation of Treg activity which may account for the detrimental effect
of anti-TNF treatment in some autoimmune diseases such as MS.
TNF-derived from activated pathogenic Teffs is critical for activa-
tion of Tregs [70]. This raises the third possibility that anti-TNF
treatment may inhibit TNF-producing capacity of Teffs and indi-
rectly blocks the stimulatory pathway of Teffs to Tregs. Despite
the mechanistic basis for its beneﬁcial effects, anti-TNF is not effec-
tive in SLE and exacerbates MS. Whether the equilibrium favors
Teffs over Tregs in these conditions has not been clariﬁed. The fac-
tors determining the outcome of anti-TNF treatment is likely to be
complicated which may include timing, location, cytokine milieu,
receptor usage, form (free vs membrane bound) and cellular source
of TNF. Given the biphasic effect of TNF on Teffs and Tregs is med-
iated by TNFR2, the expression levels of this molecule on Tregs and
Teffs is a key variable. Anti-TNF is also likely to have different effect
in Th1-dominated or Th17-dominated autoimmune disorders,
since the responses of Th1 cells and Th17 cells to Tregs and anti-
TNF are distinct. Many variables concerning TNF-TNFR2 interac-
tions need to be clariﬁed to optimize anti-TNF therapeutic strategy,
e.g., Th1 versus Th17 bias, the levels of TNFR2 on Teffs and Tregs
and levels of sTNFR2 at inﬂammatory sites. Furthermore, the pos-
sibility that TNF-TNFR1 interaction preferentially activates Teffs
should also be further studied.
Fig. 1. Natural and therapeutic resolution of inﬂammation by Tregs and anti-TNF.
In the steady state, the equilibrium of the activation of Tregs and Teffs is crucial for
immune homeostasis (1). In the early stage of inﬂammation (2), activated Teffs up-
regulate their TNFR2 expression and increase their capacity to resist Treg-mediated
inhibition, and therefore mount an effective immune response. In the later stage of
inﬂammation, Tregs outcompete with Teffs for co-stimulatory TNF-TNFR2 action
and enhanced their suppressive activity, resulting in the resolution of inﬂammatory
responses and restoration of immune homeostasis (1). However, certain types of
Teff cells (such as Th17 cells) may not be suppressed by Tregs and this causes
persistent and excessive inﬂammation (3). Anti-TNF directly inhibits activation of
Teffs and sensitizes them to Treg-mediated inhibition. Thus, intervention by anti-
TNF can resolve inﬂammation and restore the immune homeostasis (1). Under
some circumstances, such as sepsis, Tregs activated and expanded by inﬂammatory
stimulation can suppress Teffs and transiently cause immunosuppression (4).
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